GX-19

GX-19
Vaccine description
TargetSARS-CoV-2
Vaccine typeDNA
Clinical data
Other namesGX-19N
Routes of
administration		Intramuscular
Identifiers
DrugBank

GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.[1][2][3][4]

It is a DNA-based vaccine that encodes the SARS-CoV-2 spike protein.[5]

References

  1. ↑ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. United States National Library of Medicine. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
  2. ↑ "Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. 18 January 2021. Retrieved 16 March 2021.{{cite journal}}: CS1 maint: url-status (link)
  3. ↑ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  4. ↑ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
  5. ↑ Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo BS, et al. (March 2021). "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates". Vaccines. 9 (4): 307. doi:10.3390/vaccines9040307. PMC 8063950. PMID 33804981.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.